Connect Biopharma Holdings (CNTB) SEC Filings: History & Chart

Connect Biopharma Holdings Limited(CNTB)

Biotechnology · San Diego, CA

$0.91+0.01 (+0.84%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

San Diego, CA

64 employees

www.connectbiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Barry D. Quart

View full financials

Form	Filing Date	Accepted	Document
4	Oct 1, 2026	Oct 1, 2026	View filing
4	Oct 1, 2026	Oct 1, 2026	View filing
8-K	Sep 30, 2026	Sep 30, 2026	View filing
8-K	Sep 15, 2026	Sep 15, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 12, 2026	Aug 12, 2026	View filing
8-K	Aug 12, 2026	Aug 12, 2026	View filing
4	Jul 1, 2026	Jul 1, 2026	View filing
4	Jul 1, 2026	Jul 1, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
EFFECT	Jun 1, 2026	Jun 2, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
F-3	May 15, 2026	May 15, 2026	View filing
10-Q	May 12, 2026	May 12, 2026	View filing
8-K	May 12, 2026	May 12, 2026	View filing
8-K	Apr 23, 2026	Apr 23, 2026	View filing
SC 13G	Apr 14, 2026	Apr 14, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing
4	Apr 1, 2026	Apr 1, 2026	View filing
SC 13D/A	Apr 1, 2026	Apr 1, 2026	View filing
10-K	Mar 31, 2026	Mar 31, 2026	View filing
8-K	Mar 31, 2026	Mar 31, 2026	View filing
8-K	Mar 30, 2026	Mar 30, 2026	View filing
3	Mar 18, 2026	Mar 18, 2026	View filing
3	Mar 16, 2026	Mar 16, 2026	View filing
3	Mar 16, 2026	Mar 16, 2026	View filing
3	Mar 16, 2026	Mar 16, 2026	View filing
3	Mar 16, 2026	Mar 16, 2026	View filing

SEC Filings

Recent Filings